Titan expects to receive royalty payment from Fanapt net sales

Download PDF Copy

Oct 25 2010

Titan Pharmaceuticals, Inc. (OTC Bulletin Board: TTNP) today reported that the company expects to receive a royalty payment of approximately $395,000 on third quarter 2010 net sales of Fanapt (iloperidone) of approximately $4.9 million.

Prescriptions for Fanapt, an important indicator of market acceptance during product launch, showed a steady growth trend during the third quarter according to analyst reports which showed that total weekly prescriptions for Fanapt grew from approximately 1,200 prescriptions/week at the end of June to about 1,800 prescriptions/week by late September.

SOURCE Titan Pharmaceuticals, Inc.

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

High-dose inhaled nitric oxide could fight multidrug-resistant infections

Deep learning uncovers why synthetic cannabinoids cause harmful effects

Algae4IBD conference highlights seaweed-driven health innovations

Oxybutynin shows promise in managing hot flashes for prostate cancer patients

Specific gut bacteria found to drive alcohol production in patients with auto-brewery syndrome

Artificial intelligence unlocks new frontiers in RNA drug design

Solvent-free method improves drug solubility using mesoporous silica

Atypical mutation offers clues to personalized pancreatic cancer treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.